Biomarkers for risk assessment of patients with COVID-19 - Interregional Biobank project
- Funded by Novo Nordisk Foundation
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AKnown Financial Commitments (USD)
$219,552Funder
Novo Nordisk FoundationResearch Location
DenmarkLead Research Institution
Herlev & Gentofte HospitalResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Prognostic factors for disease severitySpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
The purpose of the project is to create a large, unselected biobank for patients who have been hospitalized with COVID-19. The biobank will be used for 1) identifying and comparing established as well as experimental biomarkers for serious illness and death; and 2) building a risk model that includes one or more markers as well as clinical data. The risk model can be used to assess which patients are at risk of serious illness and which patients will require less intensive monitoring, possibly from their homes. The project is a prospective cohort study.